41931-13-9
41931-13-9
Chemical Structure
LCS-1
- CAS No.: 41931-13-9
- Formula:C11H8Cl2N2O
- Molecular Weight:255.10
IUPAC Name: 4,5-dichloro-2-(m-tolyl)pyridazin-3(2H)-one
InChIKey: SYUPLLHVMCLXEM-UHFFFAOYSA-N
SMILES: O=C1C(Cl)=C(Cl)C=NN1C2=CC=CC(C)=C2
Biological Activity: LCS-1 is a superoxide dismutase 1 (SOD1) inhibitor. LCS-1 inhibits SOD1 activity with an IC50 value of 1.07 μM. LCS-1 induces the early- and late-stage apoptosis of multiple myeloma (MM.1S) cells[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
LCS-1 | 99.81% | LCS-1 is a superoxide dismutase 1 (SOD1) inhibitor. LCS-1 inhibits SOD1 activity with an IC50 value of 1.07 μM. LCS-1 induces the early- and late-stage apoptosis of multiple myeloma (MM.1S) cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.68
HY-114849Norflurazon -
Similarity Score 0.67
HY-119470Metflurazon -
Similarity Score 0.64
HY-W778236Norflurazon-13C,d3 -
Similarity Score 0.64
HY-118211EcDsbB-IN-9 -
Similarity Score 0.63
HY-117250EcDsbB-IN-10 -
Similarity Score 0.61
HY-W725574Dimidazon -
Similarity Score 0.59
HY-106885F 2692 -
Similarity Score 0.57
HY-177324Antibacterial agent 290 -
Similarity Score 0.56
HY-W1009904-Aminoantipyrine hydrochloride -
Explore the MedChemAI to find more analogs
References
- [1]. Gupta A, et al. Nanocarrier Composed of Magnetite Core Coated with Three Polymeric Shells Mediates LCS-1 Delivery for Synthetic Lethal Therapy of BLM-Defective Colorectal Cancer Cells. Biomacromolecules. 2018 Mar 12;19(3):803-815. [Content Brief]
- [2]. Somwar R, et al. Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines. Proc Natl Acad Sci U S A. 2011;108(39):16375-16380. [Content Brief]
- [3]. Du T, et al. Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13. Leukemia. 2021 Feb;35(2):550-561. [Content Brief]
